Physician profile
Patrick L Boothe
NPI 1730341694
$4,560.86
in general payments reported to CMS, 2019-2025
31 companies · $1,027 in 2025
The $1,027 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $128 · 2020: $129 · 2021: $744 · 2022: $563 · 2023: $948 · 2024: $1,023 · 2025: $1,027.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,978 · Education: $19.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,978.35 |
| Education | $19.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $553.99 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $511.25 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Chugai Pharmaceutical Co., LTD. | $400.00 | 2021 | |
| Abbott Laboratories | $388.85 | 2021-2025 | Freestyle Libre 3, Gallant |
| Astrazeneca Pharmaceuticals LP | $375.66 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $332.64 | 2022-2025 | Ubrelvy, Qulipta, Synthroid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $263.69 | 2021-2025 | Jardiance, Synjardy |
| Pfizer INC. | $256.78 | 2020-2025 | |
| Glaxosmithkline, LLC. | $170.47 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Sanofi-Aventis U.S. LLC | $141.82 | 2021-2024 | |
| Dexcom, INC. | $135.80 | 2022-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $124.41 | 2023-2025 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $117.50 | 2023-2025 | Quviviq, Quviviq |
| Eisai INC. | $113.87 | 2024-2025 | |
| Corcept Therapeutics | $84.81 | 2025 | Korlym |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $81.94 | 2023-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $69.37 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $68.81 | 2020-2024 | Seglentis, Livalo |
| Takeda Pharmaceuticals U.S.A., INC. | $63.17 | 2019-2021 | |
| Amgen INC. | $56.28 | 2024-2025 | Otezla, Repatha, Otezla |
| Abiomed | $37.44 | 2025 | |
| Renalytix Ai, INC. | $30.49 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Merck Sharp & Dohme LLC | $29.13 | 2024 | Gardasil, Capvaxive, Gardasil 9 |
| Janssen Pharmaceuticals, INC | $26.39 | 2022 | |
| Amarin Pharma, INC. | $22.30 | 2020 | |
| Phadia US INC. | $21.37 | 2021 | |
| Horizon Therapeutics Plc | $20.51 | 2019 | |
| Genentech USA, INC. | $19.68 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.88 | 2021 | |
| Medtronic, INC. | $14.57 | 2025 | O-Arm |
| Dynavax Technologies Corporation | $10.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Boothe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.